Sara A. Almadani

Medina, 42353, Saudi Arabia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Corrigendum to "Nanogel delivered benzimidazole-triazole hybrids as potent multitarget inhibitors of topoisomerase and tubulin in triple-negative breast cancer" [Bioorg. Chem. 167 (2025) 109288].

Corrigendum to "Nanogel delivered benzimidazole-triazole hybrids as potent multitarget inhibitors of topoisomerase and tubulin in triple-negative breast cancer" [Bioorg. Chem. 167 (2025) 109288].

Journal: Bioorganic chemistry

Published: December 06, 2025

Nanogel delivered benzimidazole-triazole hybrids as potent multitarget inhibitors of topoisomerase and tubulin in triple-negative breast cancer.

Nanogel delivered benzimidazole-triazole hybrids as potent multitarget inhibitors of topoisomerase and tubulin in triple-negative breast cancer.

Journal: Bioorganic chemistry

Published: October 04, 2025

ADMET, docking, anticancer evaluations, design and synthesis of pyrazolo[1,5-a]pyrimidines substituted with furan and phenyldiazene as dual EGFRT790M and VEGFR-2 inhibitors.

ADMET, docking, anticancer evaluations, design and synthesis of pyrazolo[1,5-a]pyrimidines substituted with furan and phenyldiazene as dual EGFRT790M and VEGFR-2 inhibitors.

Journal: Bioorganic chemistry

Published: May 30, 2025

Nano-carrier, design, synthesis, in silico ADMET, anti-proliferative assessments and docking of [1,2,4]triazolo[4,3-a]quinoxalines as Topo-II inhibitors and DNA intercalators.

Nano-carrier, design, synthesis, in silico ADMET, anti-proliferative assessments and docking of [1,2,4]triazolo[4,3-a]quinoxalines as Topo-II inhibitors and DNA intercalators.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: February 08, 2025

Dual VEGFR-2 and EGFRT790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis.

Dual VEGFR-2 and EGFRT790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis.

Journal: Future medicinal chemistry

Published: January 17, 2025

Exploring Azithromycin's Neuroprotective Role in Traumatic Brain Injury: Insights into Cognitive and Motor Recovery and Neuroinflammatory Modulation.

Exploring Azithromycin's Neuroprotective Role in Traumatic Brain Injury: Insights into Cognitive and Motor Recovery and Neuroinflammatory Modulation.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 01, 2024

Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR-2 and EGFRT790M: Molecular docking, ADMET, design, and syntheses.

Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR-2 and EGFRT790M: Molecular docking, ADMET, design, and syntheses.

Journal: Archiv der Pharmazie

Published: May 18, 2024

Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFRWT and EGFRT790M: design, synthesis, ADMET and molecular docking.

Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFRWT and EGFRT790M: design, synthesis, ADMET and molecular docking.

Journal: RSC advances

Published: January 19, 2024

Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.

Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.

Journal: RSC advances

Published: November 10, 2023

Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations.

Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations.

Journal: Bioorganic chemistry

Published: September 29, 2023

Modulation of NRF2/KEAP1-Mediated Oxidative Stress for Cancer Treatment by Natural Products Using Pharmacophore-Based Screening, Molecular Docking, and Molecular Dynamics Studies.

Modulation of NRF2/KEAP1-Mediated Oxidative Stress for Cancer Treatment by Natural Products Using Pharmacophore-Based Screening, Molecular Docking, and Molecular Dynamics Studies.

Journal: Molecules (Basel, Switzerland)

Published: June 23, 2023

Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.

Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.

Journal: PloS one

Published: May 04, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026